75PD - Efficacy by T categories of the postoperative adjuvant immunotherapy with ubenimex (bestatinor) on survival in patients with stage l squamous-cell l...

Date 28 March 2014
Event ELCC 2014
Session Poster Discussion 2
Topics Non-Small-Cell Lung Cancer, Early Stage
Cancer Immunology and Immunotherapy
Translational Research
Presenter Masahiro Tsuboi
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors M. Tsuboi1, H. Kato2
  • 1Thoracic Surgery & Oncology, Yokohama City University Medical Center, 232-0024 - Yokohama/JP
  • 2Thoracic Surgery & Oncology, Tokyo Medical University, 160-0023 - Tokyo/JP

 

Abstract

The 7th Edition of the TNM Classification of Malignant Tumors in non-small cell lung cancer (NSCLC) has demonstrated a more detailed classification of primary tumor diameter. Stage IA T1 disease is subdivided into two groups: T1a disease (tumor diameter, < or = 2 cm) and T1b disease (tumor diameter, >2 to < or = 3 cm). Ubenimex (BestatinR), which is a competitive protease inhibitor of aminopeptidase N (CD13) and aminopeptidase B, improves survival in patients with stage I squamous-cell lung cancer (JNCI 2003; 98:605–610). However, whether it is effective in patients with each subset of T categories, such as T1b and T2a, remains controversial. The objective of this study was to further explore the effectiveness of Ubenimex.